~/ Fourteen patients were implanted with drug pumps to provide chronic epidural or intrathecal morphine to relieve pain due to cancer. A new programmable pump was used in seven of the patients and a constant infusion device was used in the other seven patients. Results, judged by subjective pain reports (on a 0 to 10 scale), decrease in oral narcotics, and change in activity level, were excellent in eight patients, good in five patients, and poor in one patient. The programmable device has the obvious advantage of being able to vary dose according to patient need and requires less frequent refilling. Four programmable pump failures occurred, two requiring replacement.
T
HE concept of selectively infusing morphine sulfate along the spinal cord, to block pain and avoid the side effects of systemic administration, has been applied for several years. L4' 7' 13-~6 In 1981, Onofrio, et al., ~ reported the first implantation of a constant-rate drug perfusion system in a patient with a sacral chordoma. Their initial experience was encouraging and others have reported results using various external catheter systems, implanted reservoirs, and constant-rate pumps. 1' 4-6 ' 8-14"16 Ideally, an implanted drug dispensing system should provide a way to turn the device on and off, give varying rates of flow, allow single or multiple boluses, have a large enough reservoir to administer medicine over many weeks or months, be easy to implant and refill, require no replacement during the life of the patient, and give long-term reliable function. 2 A new programmable unit attempting to meet these criteria has been produced, and we report on its initial use in seven cancer patients. Experience with a previously available constant-rate infusion device 3 is also described.
Our results confirm other reports, which indicate that spinal morphine is a good method for controlling cancer pain; however, technical problems with the catheters and the programmable devices remain to be solved.
Clinical Material and Methods

Patient Selection
The basic criteria for inclusion in the study were: 1) pain due to cancer; 2) life expectancy of several months to years; 3) inability to adequately control the pain with oral narcotics or to control major side effects of narcotics (such as moderate to severe lethargy or vomiting which interfered with daily living or made home care difficult); 4) location of the pain below the midcervical dermatomes; 5) inappropriateness of standard neurosurgical procedures for pain such as chordotomy; and 6) response to a trial of epidural morphine via percutaneous catheter at the dermatome level of the pain.
Fourteen patients with intractable pain of malignant origin were selected for this trial. The group consisted of seven women and seven men (see Tables 1 and 2) . Their ages ranged from 41 to 80 years. A wide variety of malignancies are represented. This report represents 2152 days of implantation as of September 1, 1983 .
Epidural Morphine Screening
Under local anesthesia a standard epidural catheter used for anesthesia was inserted at the spinal region of the pain. Morphine sulfate (0.1 mg/cc) was infused using an external motor-driven pump. The initial dose was usually 4.8 mg/day. If this gave only partial relief, the dose was increased in steps to a maximum of 14.4 mg/day. Typically, the trial lasted 2 to 3 days, but sometimes lasted as long as 1 week. During this period, the oral narcotics were withdrawn or reduced to less than 50% of the pre-screening dose. The patient's vital signs were monitored frequently when the dose was initiated or increased. An apnea monitor and intravenous infusion system were employed and naloxone was immediately available at the bed side. In spite of the monitor and intravenous lines the patient was encouraged to ambulate so that the degree of pain relief could be judged. Patients who could not be maintained on reduced oral narcotics or who had pain relief of less than 50% on a subjective scale of 0 to 10 were not considered for implantation. No patients had significant side effects from this screening procedure other than transient urinary retention and/or itching. In particular, respiratory depression did not occur and, in fact, patients became more alert and respiratory rates increased during the trial period.
Implantation Procedure
The operations were done under local anesthesia or regional intercostal or epidural blocks. The pump was placed in a subcutaneous pocket in the abdominal wall. The epidural or intrathecal catheters were inserted under fluoroscopy using a Touhy needle and then connected to the pump by means of a shunt passer. The position of the catheter tip and location of pain are indicated in Tables 1 and 2 .
Devices
Constant Infusion Pump. The constant-rate infusion pump used was the Infusaid Model 400 pump* with a 50-cc reservoir and a side port for direct injection into the catheter. This device has been used clinically for several years and has been described in detail by several authors. :'3 The rate for drug administration was chosen to be as low as the manufacturer could provide, 1.5 to 2.5 cc/day, so that it could be refilled approximately every 3 weeks.
Programmable Pump. The programmable pump made by Medtronict uses a completely different design approach. The implanted device consists of six basic elements: a battery, a radiofrequency (RF) receiver and transmitter, a microprocessor, a reservoir, a bacterial retentive filter, and a rotary pump. The specifications for the components are given in Table 3 . To control the implanted pump, a programming device with an RF link and a printer is used. The programming device can interrogate the pump to find its functional status (on, off, drug delivery program), how much fluid is in the reservoir, if the battery has adequate capacity, and if the alarm system is functioning. The programmer can also modify the profile (drug, units), set the pump prescription, and change the amount of fluid calculated to be in the reservoir at the time of refilling. An emergency instruction to turn off the pump is always available. An audible alarm can be set to beep when the calculated reservoir volume is below a given amount, the battery is low, or the device is not functioning properly. The reservoir is filled in the same manner as in the Infusaid pump, via a special Silastic port. A standard No. 22 needle is used, and, because the reservoir is under low pressure, the fluid can be easily injected. The goal of this complex computer-based electrically controlled rotary pump is to provide a wide choice in the dose and timing of medication delivery which can be conveniently programmed and then modified as needed by the physician. The drug can be given continuously or in single or intermittent bolus form, and the dose can be controlled by rate, flow, or duration of the bolus at maximum speed. Combinations of both forms are also possible.
The programmer and its software have evolved with increasing experience. The current programmer is designed for office or hospital use and has a wide range of programs available for instructing or interrogating the pump. A smaller, hand-held programmer, will become available. This will have a simple program that can be used by the patient or family and can be pre-set by the physician to give medication only within certain limits. The catheter system is a small-bore thin Silastic tube which can be introduced through a No. 16 Touhy needle with a guide wire. Most of the units implanted had a 0.22-~M bacterial retentive filter within the pump, but three patients had pumps without filters. These systems required an implanted in-line filter external to the pump.
Results
The results for both groups of patients were evaluated by measuring the changes in the use of supplemental pain medications, the decrease in subjective pain reports utilizing the 0 to 10 scale (0 being no pain, 10 meaning the worst possible pain imaginable), and the changes in activity level. Table 1 presents a clinical summary of the patients who had the constant infusion device implanted and Table 2 the patients with the new programmable unit. The results of the continuous and the programmable drug delivery systems for this small group appear in Table 4 .
The subjective degree of pain reduction varied and was not constant over time. In one patient (Case 1) the pain lessened, and morphine sulfate via the pump could be stopped. In another patient (Case 9) with brachial plexus pain, high amputation of an edematous, immobile arm made it possible to stop the morphine infusion; later her disease progressed and the pump, which had been left in place, was again used to alleviate rib pain due to metastases. All of the patients required some adjustment of the dose, either up or down, during the course of their disease.
Objective measures of efficacy also showed improvement in all but one of the patients (Case 6). Activity levels increased as the patients became more alert and complained of less pain. All of the patients were able to return home. Oral narcotic consumption dropped considerably in most patients. However, we did not make a point of trying to take the patients off all oral narcotics. Once the patient had been withdrawn from --(never refilled) * Mean variance + expected rate. Average variance of drug delivery 6.1% for working pumps.
the high-dose systemic narcotics, the lower oral doses were much more effective for relieving mild pain and soreness.
An overall excellent response was a decrease in supplemental medicines by 50%, reduction of subjective pain to a scale of 0 to 3, and significant increase in activities of daily living. A good response was a less than 50% decrease in supplemental medicines, a subjective rating of pain between 4 and 6 and some gains in activities; a poor response was no change in supplemental medicines, a 7 to 10 rating and no change in activities. Table 4 summarizes the overall results; eight patients had excellent pain relief, five good pain relief, and one poor pain relief. These categories applied to the period during which the patients were receiving the morphine via a pump.
One patient (Case 13) developed tolerance to central narcotics after 6 weeks, but had an excellent response initially; he had been able to return to work part-time. He deteriorated rapidly because of tumor growth and developed generalized weakness, new pain in the high cervical region, increased leg pain, and marked anxiety which could only be controlled by intravenous morphine.
The programmable pump failure rate was four out of nine units. One stopped suddenly after 1 month, another decreased its flow rate after 6 months and completely stopped at 7 months, and two were found not to be functioning when the patients (Cases 2 and 5) had died. In each case the pump failure caused no morbidity as no morphine sulfate escaped into the patient. However, two patients had to re-enter the hospital for replacement in order to re-establish adequate pain relief. The cause of pump failure in two cases, on engineering analysis, was leakage of fluid into the electronic components. One pump stopped because of failure of the rotatory motor, and the cause of the last failure is still under analysis.
On one occasion (Case 3), the programmer unit failed to communicate properly; and it was replaced with a unit with a better RF signal and no further failures occurred. In two patients with the constant infusion pump (Cases 10 and 11) the catheter became dislodged. In no patients were there significant changes in respiration or blood pressure. Two patients with intrathecal catheters had post-puncture headaches which cleared in 4 and 6 days, respectively, and responded to bedrest. Transient postoperative urinary retention occurred three times and resolved in 2 to 3 days.
The average variance of drug delivery was 8.5 %, with a range of 4% to 18%, for the constant infusion pump, and 6.1%, with a range of 4.3% to 7.5%, for the programmable unit (Tables 5 and 6 ).
Discussion
Using constant infusion and programmable drug pumps to deliver morphine to the spinal cord, 13 out of 14 cancer patients had sufficient pain relief to allow care at home and resumption of some activities of daily living. While the concept of spinal infusion of mor-phine to alleviate cancer pain seems sound, a number of technical problems have marred our results. In two cases the catheter systems became dislodged, both from the subarachnoid space (Cases I0 and 11). This happened in spite of suturing the catheters in place using Silastic holding devices. Since the pump itself is well stabilized, it could act as a significant tether, and cause considerable tension on the catheter as the patient moves. Better stabilization methods are clearly needed.
Pump failure was also a significant problem for the programmable unit. The internal design of the programmable pump and assembly methods are evolving, based on this early experience, and a new design isolating the electronic parts from the fluid compartments will soon be available. The failure rate of four out of nine pumps in our series is much higher than the overall rate of eight out of 62 implanted programmable pumps achieved in clinical trials with morphine sulfate and chemotherapy (J Williams, personal communication, 1983).
The ease of reprogramming the pump and the advantages of the capability of varying doses became apparent with the first patient (Case 1). His dose of morphine sulfate was increased by steps to achieve the correct level; then, when his pain decreased, it was turned down. Subsequent experience with the other patients also indicated the convenience of slowly increasing or decreasing dosages to match the patient's changing needs. Another advantage of the programmable unit is that it does not need to be refilled frequently. The most frequent refilling time has been once a month for a patient receiving epidural morphine sulfate, but more typical is once every 2 to 4 months using the 10 mg/ml concentration.
Some further comments on the procedure should be added. A major concern has been that tolerance would develop rapidly and pain would not be relieved in spite of escalating epidural or intrathecal doses. Two such cases have been reported in the literature, and animal experiments suggest that this might be a frequent problem. 8 Fortunately, so far only one (Case 13) of our 14 patients developed clinically significant tolerance. Other patients have had to have their dose increased by up to a factor of 4, which has been easily handled by the drug pump.
Chronic intrathecal or epidural morphine did not cause any respiratory depression. Although the experience is limited, lumbar intrathecal morphine was able to relieve pain of brachial plexus origin (Cases 4 and 12). However, placement of the catheter at the same level as the pain has appeared to be more effective (Cases 7 and 14).
In conclusion, we have found chronic epidural and spinal subarachnoid morphine to be an effective method of relieving cancer pain. Both pumps, while properly functioning, give equal pain relief in cancer patients. The use of an implanted programmable pump for this purpose has many advantages but in our small series, the failure rate was four out of nine units. The current overall failure rate reported by the company is approximately 12%; this must be improved to make the unit acceptable for general use.
The programmable pump may be an excellent tool for other applications in neurosurgery. The precise and rapid control of drug infusion combined with stereotaxic placement of catheters offers a potential tool for altering neurological function and treating tumors.
